Abbott Laboratories reported quarterly earnings with higher year-over-year sales but lower net income and earnings per share, sharpening focus on upcoming estimates. The most followed narrative points to a fair value of $116.54 per share, implying the stock is 13.7% undervalued relative to its last close of $100.57. This valuation is anchored on long-term earnings and cash flow assumptions, including robust growth in branded generics and biosimilars driven by expanding healthcare access in emerging markets such as India, China, Latin America, and the Middle East. However, sustained pressure from China volume-based procurement or softer diagnostic utilization could challenge the earnings path. The stock has rallied 12.66% over the past seven days and 14.51% over the past 30 days, contrasting with a year-to-date decline of 19.02%.
Abbott LaboratoriesFair value estimate suggests 13.7% upside, implying stock is undervalued.